Russian Heart Failure Journal 2015year Diagnostic and prognostic value of new biomarkers for kidney injury in patients with acute and chronic heart failure


To access this material please log in or register

Register Authorize
2015/№1

Diagnostic and prognostic value of new biomarkers for kidney injury in patients with acute and chronic heart failure

Kuzmin O. B., Belyanin V. V., Zhezha V. V., Serdyuk S. V.
State Budgetary Educational Institution, "Orenburg State Medical Academy" of the RF Ministry of Health Care, Sovetskaya 16, Orenburg 460000

Keywords: biomarkers for kidney injury, acute heart failure, CHF

DOI: 10.18087/rhfj.2015.1.2032

The review presents results of clinical studies focused on diagnostic and prognostic value of biomarkers for kidney injury, including cystatin C, NGAL (neutral gelatinase associated lipocalin), and KIM-1 (kidney injury molecule-1) in patients with acute HF (AHF) and CHF.
  1. Ronco C, McCullough P, Anker CD et al. Cardio-renal syndromes: report from consensus conference of acute dialysis quality initiative. Eur Heart J. 2010 Mar;31 (6):703–11.
  2. Lassus J, Harjola VP. Cystatin C: a step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev. 2012 Mar;17 (2):251–61.
  3. Metha RL, Kellum JA, Shan SV et al. Acute Kidney Injury Network: report of initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11 (2):R31.
  4. Roy AK, Mc Gorrian C, Treacy C et al. A comparison of traditional and novel definition (RIFLE, AKIN, and KDIGO) of acute kidney injury for the prediction of outcomes in acute decompensated heart failure. Cardiorenal Med. 2013 Apr;3 (1):26–37.
  5. Lassus JP, Nieminen MS, Penhkurinen K et al. Markers of renal function and acute renal injury in acute heart failure: definitions and impact on outcomes of cardiorenal syndrome. Eur Heart J. 2010 Nov;31 (22):2791–8.
  6. Perez-Calvo JI, Ruiz-Ruiz FJ, Carrasco-Sanchez FJ et al. Prognostic value of serum cystatin C and N-terminal pro b-type natriuretic peptide in patients with acute heart failure. Eur J Intern Med. 2012 Oct;23 (7):599–603.
  7. Lassus JP, Harjola VP, Sund R et al. Prognostic value of cystatin C in acute heart failure in relation to their markers of renal function and NT-proBNP. Eur Heart J. 2007 Aug;28 (15):1841–7.
  8. Dupont M, Wu Y, Hasen SL, Tang WH. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ Heart Fail. 2012 Sep 1;5 (5):602–9.
  9. Zamora E, Lupon J, de Antonio M et al. Limited value of cystatin-C over estimated glomerular filtration rate for heart failure risk stratification. PLoS One. 2012;7 (12):e51234.
  10. McCullough PA, Shaw AD, Haase M et al. Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative consensus conference. Contrib Nephrol. 2013;182:13–29.
  11. Schmidt-Ott KM, Mori K, Li JY et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007 Feb;18 (2):407–13.
  12. Breidthardt T, Socrates T, Drexler B et al. Plasma neutrophil gelatinase-associated lipocalin for the prediction of acute kidney injury in acute heart failure. Crit Care. 2012 Jan 7;16 (1):R2.
  13. Mortara A, Bonadies M, Mazzetti S et al. Neutrophil gelatinase-associated lipocalin predict worsening renal function in acute heart failure: methodological and clinical issues. J Cardiovasc Med. 2013 Sep;14 (9):629–34.
  14. Ronco C, Cruz D, Noland BW. Neutrophil gelatinase-associated lipocalin curve and neutrophil gelatinase-associated lipocalin extended range assay: a new biomarker approach in the early diagnosis of acute kidney injury and cardiorenal syndrome. Semin Nephrol. 2012 Jan;32 (1):121–8.
  15. Collins SP, Hart KW, Lindsell CJ et al. Elevated urinary neutrophil gelatinase-associated lipocalin after acute heart failure treatment is associated with worsening renal function and adverse events. Eur J Heart Fail. 2012 Sep;14 (9):1020–9.
  16. Cowie MR, Komajda M, Murray-Thomas T et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results from the prospective outcomes study in heart failure (POSH). Eur Heart J. 2006 May;27 (10):1216–22.
  17. Клименко А. С., Виллевальде С. В., Кобалава Ж. Д. Клинические варианты острого почечного повреждения при декомпенсации хронической сердечной недостаточности: распространенность, тяжесть и исходы. Клиническая нефрология. 2013;5:19–26.
  18. Macdonald S, Arendts J, Nagree Y, Xu XF. Neutrophil gelatinase-associated lipocalin (NGAL) predicts renal injury in acute decompensated cardiac failure: a prospective observational study. BMC Cardiovasc Disord. 2012 Feb 17;12:8.
  19. Aghel A, Shrestha K, Mullens W et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010 Jan;16 (1):49–54.
  20. Maisel AS, Mueller C, Fitzgerald R et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail. 2011 Aug;13 (8):846–51.
  21. Shrestha K, Shao Z, Singh D et al. Relation of systemic and urinary neutrophil gelatinase-associated lipocalin levels to different aspects of impaired renal function in patients with acute decompensated heart failure. Am J Cardiol. 2012 Nov 1;110 (9):1329–35.
  22. Nymo SH, Ueland T, Askevold ET et al. The association between neutrophil gelatinase-associated lipocalin and clinical outcomes in chronic heart failure: results from CORONA. J Intern Med. 2012 May;271 (5):436–43.
  23. Damman K, van Veldhuisen DJ, Navis G et al. Urinary between neutrophil gelatinase-associated lipocalin (NGAL), a marker tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail. 2008 Oct;10 (10):997–1000.
  24. Lim AI, Tanq SC, Lai KN, Leung JC. Kidney injury molecule-1: more than just an injury marker of the epithelial cells? J Cell Physiol. 2013 May;228 (5):917–24.
  25. de Geus HR, Fortrie G, Betjes MG et al. Time of urinary affects urinary biomarker predictive value for acute kidney injury in critically ill non-septic patients. BMC Nephrol. 2013 Dec 9;14:273.
  26. Liangos O, Perianayagam MC, Vaidya VS et al. Urinary N-acetyl-beta- (D) – glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007 Mar;18 (3):904–12.
  27. Damman K, van Veldhuisen DJ, Navis G et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart. 2010 Aug;96 (16):1297–302.
  28. Jungbauer CG, Birner C, Jung B et al. Kidney injury molecule-1 and N-acetyl-β-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur J Heart Fail. 2011 Oct;13 (10):1104–10.
  29. Damman K, Masson S, Hillege HL et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J. 2011 Nov;32 (21):2705–12.
  30. Damman K, Masson S, Hillege HL et al. Tubular damage and worse­ning renal function in chronic heart failure. JACC Heart Fail. 2013 Oct;1 (5):417–24.
  31. Кузьмин О. Б., Белянин В. В., Жежа В. В. Легкая дисфункция почек у больных сердечной недостаточностью: доклинические признаки и их прогностическое значение. Журнал Сердечная Недостаточность. 2014;15 (2):126–31.
Kuzmin O. B., Belyanin V. V., Zhezha V. V. et al. Diagnostic and prognostic value of new biomarkers for kidney injury in patients with acute and chronic heart failure. Russian Heart Failure Journal. 2015;16 (1):57–64

To access this material please log in or register

Register Authorize
Ru En